^
Association details:
| Biomarker: | ASS1 negative |
|---|---|
| Cancer: | Uveal Melanoma |
| Drug: | cisplatin (DNA synthesis inhibitor) + pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor) + Hepacid (pegargiminase) (Arginine depleter) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma
Published date:
04/25/2022
Excerpt:
Ten of fourteen ASS1-deficient patients with UM liver metastases and a median of one line of prior immunotherapy received ADIPemCis….Seven patients had stable disease with a median progression-free survival of 3.0 months (range, 1.3-8.1) and a median overall survival of 11.5 months (range, 3.2-36.9).
DOI:
10.1111/pcmr.13042
